The Correlation Between The Concentration Of Paliperidone And The Dose, Clinical Efficacy, Side Effects In Schizophrenia

Objective1.To evaluate the clinical efficacy and safety of Paliperidone in the treatment of schizophrenia.2.To explore the correlation between the concentration of Paliperidone and the dose, the clinical efficacy and the side effects.MethodsOur study was based on the definition of CKD from K/DOQI guide made by American kidney foundation (NKF).35patients were chosen for the study. Measurements the concentration of Paliperidone in serum for everyone by reversed phase high performance liquid chromatography,respectively at the week1,2,4. Evaluation the clinical efficacy of Paliperidone by the positive and negative symptoms scale (PANSS) at the week1,2,4,8, and the TESS scale was used to evaluate the adverse events. Measurements the following biochemical index at the week1,4:routine blood and urine, liver and kidney function, electrocardiogram and prolactin levels.Results1.In our study,23people in the35finished the experiment. Compared to the baseline, the scores of PANSS, SAPS, SANS, PSY, CGI-Spoints have significant difference at the week8(P<0.05). There is no difference between starting and the relapse schizophrenia patients (P>0.05). During the treatment of paliperidone, the main adverse reactions were dizziness, dry mouth, nasal congestion, blurred vision, sleepiness, tachycardia, fatigue, insomnia and extrapyramidal symptoms. Serum prolactin was significantly increased after the treatment both male and female patients (P<0.05), however the elevations has no obvious differences between the two groups(P>0.05). At the week8, the average weight had a significant increaseing (2.46+/-2.45Kg)(P<0.01). And the Total cholesterol, triglycerides, high-density lipoprotein cholesterol (hdl-c), low density lipoprotein cholesterol (hdl-c) value increased. Compared to the baseline, the difference was statistically significant (P<0.05)2.The concentration of Paliperidone at the week1and2are different (P<0.05), but there was no difference between the week2and week4(P>0.05).There was difference between male and female patients in the same dose. The concentration of paliperidone wass positively correlated with the dose of1,2,4weekend (P<0.05),but no correlation with PANSS scores, factor score points reduction rate, CGI-S, TESS and the added value of weight. There was no difference in the concentration neither between effective and ineffective group (P>0.05), nor between EPS and no-EPS (P>0.05).The concentration of paliperidone was correlation of serum prolactin in female patients (P<0.05)Conclusion1.Paliperidone can take effect in1week, which improving the positive and negative symptoms and mental pathological symptoms.2.Paliperidone was efficacy for both starting and relapse of schizophrenia.3.There are few adverse reaction of Paliperidone, the main side effects are extrapyramidal syndrome, higher serum prolactin,mild weight gain, increased blood lipid mild.4.The concentration of Paliperidone is dose related.5.The concentration of Paliperidone is associated with increased serum prolactin in female.